English
Regional settings| Spread | 0.0031 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 0.9936 |
| Open | 0.9957 |
| 1-Year Change | -67.03% |
| Day's Range | 0.9956 - 0.9971 |
Berkeley Lights, Inc. is a digital cell biology company. The Company is focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The Company's Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for tens of thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Berkeley Lights platform is a fully integrated, end-to-end solution, consisting of consumables, including its OptoSelect chips and reagent kits, advanced automation systems, and advanced application and workflow software. The Company's platform leverages its OptoElectro Positioning (OEP) technology, which provides deterministic positioning of living single cells and other micro-objects using light. The Company's software products include Cell Analysis Suite (CAS), Workflow Runner/Builder, Assay Analyzer, Image Analyzer, and PrimeSeq.
BRIEF: For the fiscal year ended 31 December 2021, Berkeley Lights Inc revenues increased 33% to $85.4M. Net loss applicable to common stockholders increased 66% to $71.7M. Revenues reflect Antibody Therapeutics segment increase of 24% to $64.3M, Synthetic Biology segment increase of 11% to $9M, Asia Pacific segment increase of 82% to $35.2M, North America segment increase of 27% to $41.2M.
